We also noted that RMC tumor cells treated with ICT overexpress IFNGR1 and that genetic knockout of IFNGR1 prevented hyperprogression and sensitized tumors to ICT in pre-clinical settings. The gene discussed is IFNGR1; the disease is neoplasm.